MA43082A1 - Conjugue d'enzymes thérapeutiques - Google Patents

Conjugue d'enzymes thérapeutiques

Info

Publication number
MA43082A1
MA43082A1 MA43082A MA43082A MA43082A1 MA 43082 A1 MA43082 A1 MA 43082A1 MA 43082 A MA43082 A MA 43082A MA 43082 A MA43082 A MA 43082A MA 43082 A1 MA43082 A1 MA 43082A1
Authority
MA
Morocco
Prior art keywords
conjugate
therapeutic enzymes
immunoglobulin
connecting portion
relates
Prior art date
Application number
MA43082A
Other languages
English (en)
Inventor
Dae Jin Kim
Jung Kuk Kim
Sung Youb Jung
Se Chang Kwon
Original Assignee
Hanmi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharma Co Ltd filed Critical Hanmi Pharma Co Ltd
Publication of MA43082A1 publication Critical patent/MA43082A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/321—Polymers modified by chemical after-treatment with inorganic compounds
    • C08G65/328—Polymers modified by chemical after-treatment with inorganic compounds containing other elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un ensemble de couplage dans lequel une région fc d'immunoglobuline est couplée à des enzymes thérapeutiques à travers une partie de connexion de polymère non peptidique, et concerne : un ensemble de couplage dans lequel une partie de connexion de polymère non peptidique est spécifiquement couplée à un fc d'immunoglobuline; son procédé de production; et une composition le contenant.
MA43082A 2016-01-29 2017-01-31 Conjugue d'enzymes thérapeutiques MA43082A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160011886 2016-01-29
PCT/KR2017/001016 WO2017131496A1 (fr) 2016-01-29 2017-01-31 Ensemble de couplage pour enzymes thérapeutiques

Publications (1)

Publication Number Publication Date
MA43082A1 true MA43082A1 (fr) 2018-10-31

Family

ID=59398822

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43082A MA43082A1 (fr) 2016-01-29 2017-01-31 Conjugue d'enzymes thérapeutiques

Country Status (23)

Country Link
US (1) US10918736B2 (fr)
EP (1) EP3409771A4 (fr)
JP (2) JP7356222B2 (fr)
KR (1) KR20170091056A (fr)
CN (1) CN108884455A (fr)
AR (2) AR107483A1 (fr)
AU (1) AU2017210871A1 (fr)
BR (1) BR112018015603A2 (fr)
CA (1) CA3012982A1 (fr)
CL (2) CL2018002045A1 (fr)
CO (1) CO2018008427A2 (fr)
CR (1) CR20180393A (fr)
EA (1) EA201891573A1 (fr)
EC (1) ECSP18062538A (fr)
HK (1) HK1257558A1 (fr)
MA (1) MA43082A1 (fr)
MX (1) MX2018009266A (fr)
PH (1) PH12018501612A1 (fr)
SG (1) SG11201806502UA (fr)
TN (1) TN2018000270A1 (fr)
TW (1) TW201729846A (fr)
WO (1) WO2017131496A1 (fr)
ZA (1) ZA201805634B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
JP7187024B2 (ja) 2016-07-01 2022-12-12 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的化された細胞表面編集のための複合体
US20200078470A1 (en) 2016-12-05 2020-03-12 Hanmi Pharm. Co., Ltd. Conjugate with attenuated immune response
CN111094559A (zh) * 2017-07-07 2020-05-01 韩美药品株式会社 新型治疗酶融合蛋白及其用途
CA3076369A1 (fr) 2017-10-02 2019-04-11 Denali Therapeutics Inc. Proteines de fusion comprenant des enzymes d'enzymotherapie substitutive
WO2019124973A1 (fr) * 2017-12-19 2019-06-27 재단법인 목암생명과학연구소 Conjugué de protéine et protéine de fusion qui comprennent de l'albumine et une enzyme lysosomale
BR112020012346A2 (pt) * 2017-12-22 2020-11-24 Hanmi Pharm. Co., Ltd. proteína de fusão enzimática terapêutica tendo uma nova estrutura e uso da mesma
AU2019205912A1 (en) 2018-01-03 2020-07-16 Palleon Pharmaceuticals Inc. Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
JP2023549323A (ja) * 2020-11-13 2023-11-24 ハンミ ファーマシューティカル カンパニー リミテッド 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途
US20230416714A1 (en) * 2020-11-13 2023-12-28 Hanmi Pharm. Co., Ltd Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (fr) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Domaines analogues a l'immunoglobuline a demi-vies prolongees
KR100396983B1 (ko) * 2000-07-29 2003-09-02 이강춘 고반응성의 가지 달린 고분자 유도체 및 고분자와 단백질또는 펩타이드의 접합체
WO2005047334A1 (fr) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical. Co., Ltd. Fragment d'igg fc pour vecteur de medicament et procede de preparation associe
KR100754667B1 (ko) * 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP3173484B1 (fr) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Protéines de fusion d'immunoglobuline
PT2490533E (pt) 2009-10-19 2016-01-13 Amicus Therapeutics Inc Novas composições para a prevenção e/ou tratamento de distúrbios de depósito lisossómico
DK2685986T3 (da) 2011-03-18 2020-03-02 Genzyme Corp Glucosylceramidsyntasehæmmer
KR102041412B1 (ko) * 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
WO2015009052A1 (fr) 2013-07-16 2015-01-22 일동제약 주식회사 Protéine de fusion de fc hybride d'immunoglobuline et d'enzyme
US20160243260A1 (en) 2013-10-24 2016-08-25 Uniqure Ip B.V. Treatment of neurological diseases using adeno-associated virus (AAV) comprising AAV-5 capsid proteins
AR107483A1 (es) * 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas

Also Published As

Publication number Publication date
KR20170091056A (ko) 2017-08-08
MX2018009266A (es) 2019-01-10
PH12018501612A1 (en) 2019-04-08
AR120515A2 (es) 2022-02-23
EP3409771A1 (fr) 2018-12-05
CN108884455A (zh) 2018-11-23
TN2018000270A1 (en) 2020-01-16
US10918736B2 (en) 2021-02-16
TW201729846A (zh) 2017-09-01
ECSP18062538A (es) 2018-09-30
BR112018015603A2 (pt) 2018-12-26
CO2018008427A2 (es) 2018-10-31
AR107483A1 (es) 2018-05-02
JP7356222B2 (ja) 2023-10-04
CL2020001857A1 (es) 2020-10-02
SG11201806502UA (en) 2018-08-30
CA3012982A1 (fr) 2017-08-03
EA201891573A1 (ru) 2019-02-28
HK1257558A1 (zh) 2019-10-25
CR20180393A (es) 2019-02-12
ZA201805634B (en) 2019-06-26
AU2017210871A1 (en) 2018-08-30
JP2019506164A (ja) 2019-03-07
CL2018002045A1 (es) 2018-08-31
US20190046657A1 (en) 2019-02-14
EP3409771A4 (fr) 2019-10-23
JP2022046524A (ja) 2022-03-23
WO2017131496A1 (fr) 2017-08-03

Similar Documents

Publication Publication Date Title
MA43082A1 (fr) Conjugue d'enzymes thérapeutiques
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
MA40662A1 (fr) Anticorps contre tigit
MA30394B1 (fr) Synthese d'acylaminoalcenylene-amides pouvant etre employes en tant qu'antagonistes de la substance p
MD3823665T2 (ro) Receptori antigenci chimerici cu specificitate BCMA și utilizările acestora
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
MA39225A1 (fr) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
MA31984B1 (fr) Formulation d'anticorps
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA43364B1 (fr) Composés d'alcènes tétrasubstitués et leur utilisation
MA31904B1 (fr) Anticorps bispecifiques bivalents
MA33405B1 (fr) Anticorps anti-axl
FR2985274B1 (fr) Structures fibreuses comprenant des particules et leur procede de fabrication
PE20121542A1 (es) Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados
MA34641B1 (fr) Anticorps anti-il-23
FR3029790B1 (fr) Microbille d'hydrogel de chitosane
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
MA38816A (fr) Sulfamidase modifiée et sa production
FR3056398B1 (fr) Ventouse de massage
CL2023002393A1 (es) Anticuerpos anti-cd30l y usos de estos
PE20091969A1 (es) ANTICUERPOS ANTI-PirB
FR2955028B1 (fr) Traitement des infections par les chlamydiaceae par les beta-lactames
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur